TY - JOUR
T1 - Cardiovascular care facts
T2 - A report from the national cardiovascular data registry: 2011
AU - Masoudi, Frederick A.
AU - Ponirakis, Angelo
AU - Yeh, Robert W.
AU - Maddox, Thomas M.
AU - Beachy, Jim
AU - Casale, Paul N.
AU - Curtis, Jeptha P.
AU - de Lemos, James A
AU - Fonarow, Gregg
AU - Heidenreich, Paul
AU - Koutras, Christina
AU - Kremers, Mark
AU - Messenger, John
AU - Moussa, Issam
AU - Oetgen, William J.
AU - Roe, Matthew T.
AU - Rosenfield, Kenneth
AU - Shields, Thomas P.
AU - Spertus, John A.
AU - Wei, Jessica
AU - White, Christopher
AU - Young, Christopher H.
AU - Rumsfeld, John S.
N1 - Funding Information:
Dr. Masoudi has a contract with the American College of Cardiology Foundation (ACCF) for his role as Senior Medical Officer of the NCDR (National Cardiovascular Data Registry). Dr. Ponirakis, Mr. Beachy, Mrs. Koutras, Dr. Oetgen, Mr. Shields, and Ms. Wei are employed by the American College of Cardiology Foundation (ACCF). Dr. Maddox is Chair of the PINNACLE (Practice INNovation And CLinical Excellence) Registry Research & Publication Committee and is funded by a VA Health Services Research & Development Career Development Award. Dr. Casale is the Chair of the PINNACLE Registry Steering Committee. Dr. Curtis receives salary support through a contract with the American College of Cardiology to provide data analytic services, salary support under contract with Centers for Medicaid and Medicare Services to develop and maintain quality measures, reports stock holding in Medtronic, and has received research funding from Boston Scientific . Dr. De Lemos receives grant support from Roche Diagnostics and Abbott Diagnostics ; consulting fees from Janssen Pharmaceuticals; and honoraria from Astra Zeneca and BMS. Dr. Fonarow receives research support from the Agency for Healthcare Research and Quality ; serves as a consultant for Novartis, Medtronic, and Gambro; and has served as unpaid Chair of the ACTION Registry-GWTG Steering Committee. Dr. Kremers has equity >$10K in Boston Scientific; provides consulting for Medtronic; is a member of the Speakers’ bureau for Boston Scientific; and is an investigator for St. Jude Medical, Medtronic, Boston Scientific, and Cameron Health. Dr. Messenger is Chair of the CathPCI Registry Research and Publication Committee. Dr. Moussa is an investigator on research protocols sponsored by Medtronic, Gilead, Baxter, and Terumo. Dr. Roe has received research funding from Eli Lilly, Revalesio, Sanofi-Aventis, American College of Cardiology, American Heart Association ; and consulting fees or honoraria from AstraZeneca, Sanofi-Aventis, Janssen Pharmaceuticals, Merck, Regeneron, and Daiichi-Sankyo. Dr. Rosenfield has received research grants from Abbott Vascular, Atrium, Lutronix-Bard, Baxter, and IDEV; has received consulting/advisory board fees from Abbott Vascular, Complete Conference Management, Endospan, Micell and Vortex-AngioDynamics; has equity in CardioMEMs, Contego, Embolitech, Icon, Micell, Primacea, and Vortex; and has served on the board of directors for VIVA Physicians (501C3). Dr. Spertus is affiliated with the Saint Luke’s Mid America Heart and Institute, which is the major analytic center for the PINNACLE Registry; receives funding from the American College of Cardiology for this role; is on the Scientific Advisory Board of United Healthcare; and reports a financial relationship with Health Outcomes Sciences. Dr. Rumsfeld has a contract with the ACCF for his role as the Chief Medical Officer of the NCDR. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
The ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry–GWTG (Get With The Guidelines) is sponsored by the ACCF in conjunction with the American Heart Association, with partnering support from the Society of Cardiovascular Patient Care, The American College of Emergency Physicians, and The Society of Hospital Medicine (3) . The ACTION Registry–GWTG was designed to assess the characteristics, treatments, and outcomes of acute myocardial infarction (AMI) patients (either ST-segment elevation myocardial infarction or non–ST-segment elevation myocardial infarction). Eligible patients are those older than 18 years of age hospitalized with a diagnosis of AMI who have acute ischemic symptoms within 24 h of presentation. Patients admitted for other conditions who subsequently develop AMI during hospital stay are not included ( Figs. 1 to 6 , Tables 1 to 6 ).
PY - 2013/11/19
Y1 - 2013/11/19
N2 - Objectives The aim of this report was to characterize the patients, participating centers, and measures of quality of care and outcomes for 5 NCDR (National Cardiovascular Data Registry) programs: 1) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-GWTG (Get With The Guidelines) for acute coronary syndromes; 2) CathPCI Registry for coronary angiography and percutaneous coronary intervention; 3) CARE (Carotid Artery Revascularization and Endarterectomy) Registry for carotid revascularization; 4) ICD Registry for implantable cardioverter defibrillators; and the 5) PINNACLE (Practice INNovation And CLinical Excellence) Registry for outpatients with cardiovascular disease (CVD). Background CVD is a leading cause of death and disability in the United States. The quality of care for patients with CVD is suboptimal. National registry programs, such as NCDR, permit assessments of the quality of care and outcomes for broad populations of patients with CVD. Methods For the year 2011, we assessed for each of the 5 NCDR programs: 1) demographic and clinical characteristics of enrolled patients; 2) key characteristics of participating centers; 3) measures of processes of care; and 4) patient outcomes. For selected variables, we assessed trends over time. Results In 2011 ACTION Registry-GWTG enrolled 119,967 patients in 567 hospitals; CathPCI enrolled 632,557 patients in 1,337 hospitals; CARE enrolled 4,934 patients in 130 hospitals; ICD enrolled 139,991 patients in 1,435 hospitals; and PINNACLE enrolled 249,198 patients (1,436,328 individual encounters) in 74 practices (1,222 individual providers). Data on performance metrics and outcomes, in some cases risk-adjusted with validated NCDR models, are presented. Conclusions The NCDR provides a unique opportunity to understand the characteristics of large populations of patients with CVD, the centers that provide their care, quality of care provided, and important patient outcomes.
AB - Objectives The aim of this report was to characterize the patients, participating centers, and measures of quality of care and outcomes for 5 NCDR (National Cardiovascular Data Registry) programs: 1) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-GWTG (Get With The Guidelines) for acute coronary syndromes; 2) CathPCI Registry for coronary angiography and percutaneous coronary intervention; 3) CARE (Carotid Artery Revascularization and Endarterectomy) Registry for carotid revascularization; 4) ICD Registry for implantable cardioverter defibrillators; and the 5) PINNACLE (Practice INNovation And CLinical Excellence) Registry for outpatients with cardiovascular disease (CVD). Background CVD is a leading cause of death and disability in the United States. The quality of care for patients with CVD is suboptimal. National registry programs, such as NCDR, permit assessments of the quality of care and outcomes for broad populations of patients with CVD. Methods For the year 2011, we assessed for each of the 5 NCDR programs: 1) demographic and clinical characteristics of enrolled patients; 2) key characteristics of participating centers; 3) measures of processes of care; and 4) patient outcomes. For selected variables, we assessed trends over time. Results In 2011 ACTION Registry-GWTG enrolled 119,967 patients in 567 hospitals; CathPCI enrolled 632,557 patients in 1,337 hospitals; CARE enrolled 4,934 patients in 130 hospitals; ICD enrolled 139,991 patients in 1,435 hospitals; and PINNACLE enrolled 249,198 patients (1,436,328 individual encounters) in 74 practices (1,222 individual providers). Data on performance metrics and outcomes, in some cases risk-adjusted with validated NCDR models, are presented. Conclusions The NCDR provides a unique opportunity to understand the characteristics of large populations of patients with CVD, the centers that provide their care, quality of care provided, and important patient outcomes.
KW - cardiovascular disease
KW - quality of care
KW - registries
KW - registry
UR - http://www.scopus.com/inward/record.url?scp=84886857186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886857186&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2013.05.099
DO - 10.1016/j.jacc.2013.05.099
M3 - Article
C2 - 24036027
AN - SCOPUS:84886857186
VL - 62
SP - 1931
EP - 1947
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 21
ER -